Adelya F. Karimova

Adelya F. Karimova

Auto-generated profile, based on publicly available information

Adelya F. Karimova

Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan, Russia

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 February 2025 in European Journal of Cancer
Verified
Journal Article
Open access
AKAdelya F. Karimova
Adelya F. Karimova
AKAdelya R. Khalitova
Adelya R. Khalitova
RSRoman Suezov
Roman Suezov
NMNikita Markov
Nikita Markov
YMYana Mukhamedshina
Yana Mukhamedshina
ABAnna Brichkina
Anna Brichkina
Tumor-associated macrophages (TAMs) play a pivotal role in the tumor microenvironment (TME), actively contributing to the formation of an immunosuppressive niche that fosters tumor progression. Consequently, there has been a growing interest in targeting TAMs as a promising avenue for cancer therapy. Recent advances in the field of immunometabolism have shed light on the influence of metabolic adaptations on macrophage physiology in the context of cancer. Here, we discuss the key metabolic pathways that shape the phenotypic diversity of macrophages. We place special emphasis on how metabolic reprogramming impacts the activation status of TAMs and their functions within the TME. Additionally, we explore alterations in TAM metabolism and their effects on phagocytosis, production of cytokines/chemokines and interaction with cytotoxic T and NK immune cells. Moreover, we examine the application of nanomedical approaches to target TAMs and assess the clinical significance of modulating the metabolism of TAMs as a strategy to develop new anti-cancer therapies. Taken together, in this comprehensive review article focusing on TAMs, we provide invaluable insights for the development of effective immunotherapeutic strategies and the enhancement of clinical outcomes for cancer patients.

20 June 2024 in The FASEB Journal
Verified
Journal Article
Open access
AKAdelya F. Karimova
Adelya F. Karimova
AKAvanee Ketkar
Avanee Ketkar
RSRoman Suezov
Roman Suezov
AKAdelya R. Khalitova
Adelya R. Khalitova
Marina GomzikovaMarina Gomzikova
Marina Gomzikova
ABAnna Brichkina
Anna Brichkina
Tumor‐associated macrophages (TAMs) are integral components of the tumor microenvironment. They are involved in various aspects of tumor cell biology, driving pathological processes such as tumor cell proliferation, metastasis, immunosuppression, and resistance to therapy. TAMs exert their tumorigenic effects by secreting growth factors, cytokines/chemokines, metabolites, and other soluble bioactive molecules. These mediators directly promote tumor cell proliferation and modulate interactions with immune and stromal cells, facilitating further tumor growth. As research into therapies targeting TAMs intensifies, there is a growing need for reliable methods to comprehend the impact of TAMs on cancer progression and to validate novel therapeutics directed at TAMs. The traditional “M1‐M2” macrophage classification based on transcriptional profiles of TAMs is not only too simplistic to describe their physiological roles, it also does not explain differences observed between mouse and human macrophages. In this context, methods that assess how TAMs influence tumor or immune cells, either through direct contact or the release of soluble factors, offer a more promising approach. We describe here comprehensive protocols for in vitro functional assays to study TAMs, specifically regarding their impact on the growth of lung cancer cells. We have applied these methods to both mouse and human macrophages, achieving similar outcomes in promoting the proliferation of cancer cells. This methodology can serve as a standardized approach for testing novel therapeutic approaches, targeting TAMs with novel immunotherapeutic compounds, or utilizing gene‐editing techniques. Taken together, the described methodology may contribute to our understanding of complex macrophage‐tumor interactions and support the development of innovative therapeutic strategies.